Online inquiry

IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10629MR)

This product GTTS-WQ10629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MAPT gene. The antibody can be applied in Dementia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001123066.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4137
UniProt ID P10636
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10629MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14882MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ11990MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ15038MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ8854MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ13318MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ722MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ11753MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ6387MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW